WallStreetZenWallStreetZen

NASDAQ: SXTP
60 Degrees Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SXTP

Based on 2 analysts offering 12 month price targets for 60 Degrees Pharmaceuticals Inc

Min Forecast
$11.20+169.88%
Avg Forecast
$17.60+324.1%
Max Forecast
$24.00+478.31%

Should I buy or sell SXTP stock?

Based on 2 analysts offering ratings for 60 Degrees Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SXTP stock forecasts and price targets.

SXTP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-27
lockedlocked$00.00+00.00%2025-11-28

1 of 1

Forecast return on equity

Is SXTP forecast to generate an efficient return?

Company
N/A
Industry
256.02%
Market
237.79%

Forecast return on assets

Is SXTP forecast to generate an efficient return on assets?

Company
N/A
Industry
96.9%

SXTP earnings per share forecast

What is SXTP's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.76
Avg 2 year Forecast
-$0.48

SXTP revenue forecast

What is SXTP's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$2.1M+69.88%
Avg 2 year Forecast
$3.9M+213.37%
Avg 3 year Forecast
$3.1M+148.61%
SXTP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SXTP revenue growth forecast

How is SXTP forecast to perform vs Biotechnology companies and vs the US market?

Company
55.22%
Industry
325.85%
Market
56.5%
SXTP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SXTP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SXTP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SXTP$4.15$17.60+324.10%Buy
DCOY$0.77$2.50+224.25%Strong Buy
SILO$0.35N/AN/A
GRI$3.26$1,008.00+30,820.25%Buy
MLEC$6.50N/AN/A
View Top Biotech Stocks

60 Degrees Pharmaceuticals Stock Forecast FAQ

Is 60 Degrees Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SXTP) stock is to Buy SXTP stock.

Out of 2 analysts, 0 (0%) are recommending SXTP as a Strong Buy, 2 (100%) are recommending SXTP as a Buy, 0 (0%) are recommending SXTP as a Hold, 0 (0%) are recommending SXTP as a Sell, and 0 (0%) are recommending SXTP as a Strong Sell.

If you're new to stock investing, here's how to buy 60 Degrees Pharmaceuticals stock.

What is SXTP's earnings growth forecast for 2026-2027?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 135.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.53%.

60 Degrees Pharmaceuticals's earnings in 2026 is -$8,470,732.On average, 4 Wall Street analysts forecast SXTP's earnings for 2026 to be -$1,860,868, with the lowest SXTP earnings forecast at -$2,041,826, and the highest SXTP earnings forecast at -$1,643,529.

In 2027, SXTP is forecast to generate -$507,019 in earnings, with the lowest earnings forecast at -$487,136 and the highest earnings forecast at -$521,932.

What is SXTP's revenue growth forecast for 2026-2028?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual revenue growth rate of 55.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 325.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 56.5%.

60 Degrees Pharmaceuticals's revenue in 2026 is $1,230,833.On average, 4 Wall Street analysts forecast SXTP's revenue for 2026 to be $2,211,467, with the lowest SXTP revenue forecast at $1,761,982, and the highest SXTP revenue forecast at $2,665,182. On average, 3 Wall Street analysts forecast SXTP's revenue for 2027 to be $4,079,209, with the lowest SXTP revenue forecast at $3,918,452, and the highest SXTP revenue forecast at $4,198,720.

In 2028, SXTP is forecast to generate $3,236,293 in revenue, with the lowest revenue forecast at $3,109,379 and the highest revenue forecast at $3,331,478.

What is SXTP's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: SXTP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 96.9%.

What is SXTP's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SXTP price target, the average SXTP price target is $17.60, with the highest SXTP stock price forecast at $24.00 and the lowest SXTP stock price forecast at $11.20.

On average, Wall Street analysts predict that 60 Degrees Pharmaceuticals's share price could reach $17.60 by Jan 27, 2027. The average 60 Degrees Pharmaceuticals stock price prediction forecasts a potential upside of 324.1% from the current SXTP share price of $4.15.

What is SXTP's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's current Earnings Per Share (EPS) is -$0.84. On average, analysts forecast that SXTP's EPS will be -$1.76 for 2026, with the lowest EPS forecast at -$1.93, and the highest EPS forecast at -$1.55. In 2027, SXTP's EPS is forecast to hit -$0.48 (min: -$0.46, max: -$0.49).

What is SXTP's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: SXTP) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.